King Esther A, Challa Sridevi, Curtin Patrick, Bielory Leonard
Department of Pharmacy, Atlantic Health System, Overlook Medical Center, Summit, New Jersey.
Department of Medicine, Banner Baywood Medical Center, Mesa, Arizona.
Ann Allergy Asthma Immunol. 2016 Jul;117(1):67-71. doi: 10.1016/j.anai.2016.04.021. Epub 2016 May 20.
A history of a penicillin allergy generally leads to the use of broad-spectrum antibiotics that may increase complications and cost.
To determine the cost-effectiveness of performing penicillin skin testing (PST).
A retrospective analysis was conducted on adult inpatients with a β-lactam allergy who underwent PST and oral challenge performed by an allergist. The primary outcome was overall antibiotic cost savings for patients switched to a β-lactam antibiotic (BLA). Secondary outcomes included subsequent admissions that required antibiotics and total number of days a BLA was prescribed.
Fifty patients had PST performed (mean age, 62 years). The most common β-lactam allergy reported was penicillin (92%). Cutaneous reactions were reported in 54% of patients, and 56% had a reaction more than 20 years ago. Fifty percent of patients had aztreonam prescribed before PST. The results of PST were negative in all patients, and 1 patient had anaphylactic symptoms during the oral amoxicillin challenge (98% skin test or oral challenge negative). Thirty-seven patients (75.5%) were changed to a BLA. Overall cost savings were $11,005 ($297 per patient switched to a BLA). There were 31 subsequent admissions that required antibiotics for patients who tested negative on skin test and oral challenge. A BLA was prescribed in 22 of 31 readmissions, totaling 147 days of BLA therapy.
After the implementation of a PST protocol, we observed a decrease in non-BLA use in patients with previously documented β-lactam allergy. PST is a safe and cost-effective procedure to serve as a negative predictor test for penicillin hypersensitivity mediated by IgE.
青霉素过敏史通常会导致使用可能增加并发症和成本的广谱抗生素。
确定进行青霉素皮肤试验(PST)的成本效益。
对接受过敏专科医生进行PST和口服激发试验的β-内酰胺类过敏成年住院患者进行回顾性分析。主要结局是改用β-内酰胺类抗生素(BLA)的患者的总体抗生素成本节省。次要结局包括随后需要使用抗生素的入院次数以及开具BLA的总天数。
50例患者进行了PST(平均年龄62岁)。报告的最常见β-内酰胺类过敏是青霉素(92%)。54%的患者报告有皮肤反应,56%的患者在20多年前有过反应。50%的患者在PST前使用了氨曲南。所有患者的PST结果均为阴性,1例患者在口服阿莫西林激发试验期间出现过敏症状(98%的皮肤试验或口服激发试验阴性)。37例患者(75.5%)改用了BLA。总体成本节省为11,005美元(每位改用BLA的患者节省297美元)。皮肤试验和口服激发试验阴性的患者中有31次随后需要使用抗生素的入院。31次再入院中有22次开具了BLA,BLA治疗总天数为147天。
实施PST方案后,我们观察到既往有β-内酰胺类过敏记录的患者中,非BLA的使用有所减少。PST是一种安全且具有成本效益的程序,可作为IgE介导的青霉素超敏反应的阴性预测试验。